Johnson & Johnson (NYSE:JNJ) Shares Purchased by Community Bank N.A.

Community Bank N.A. lifted its position in Johnson & Johnson (NYSE:JNJGet Rating) by 1.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 71,889 shares of the company’s stock after purchasing an additional 1,159 shares during the period. Johnson & Johnson comprises about 1.8% of Community Bank N.A.’s portfolio, making the stock its 9th biggest holding. Community Bank N.A.’s holdings in Johnson & Johnson were worth $11,744,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in JNJ. Morton Brown Family Wealth LLC increased its holdings in Johnson & Johnson by 78.0% in the 2nd quarter. Morton Brown Family Wealth LLC now owns 178 shares of the company’s stock worth $32,000 after acquiring an additional 78 shares in the last quarter. Goodman Advisory Group LLC purchased a new stake in Johnson & Johnson in the 2nd quarter worth $39,000. Cardinal Capital Management Inc. increased its holdings in Johnson & Johnson by 333.3% in the 2nd quarter. Cardinal Capital Management Inc. now owns 260 shares of the company’s stock worth $46,000 after acquiring an additional 200 shares in the last quarter. First Bank & Trust grew its holdings in shares of Johnson & Johnson by 69.6% during the second quarter. First Bank & Trust now owns 380 shares of the company’s stock worth $67,000 after buying an additional 156 shares in the last quarter. Finally, Heritage Wealth Management LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth $84,000. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

JNJ has been the subject of a number of research reports. Barclays initiated coverage on shares of Johnson & Johnson in a report on Monday, October 17th. They set an “equal weight” rating and a $175.00 target price for the company. Sanford C. Bernstein dropped their target price on shares of Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Credit Suisse Group initiated coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 target price for the company. StockNews.com began coverage on shares of Johnson & Johnson in a report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Finally, Raymond James dropped their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, October 19th. Seven research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $182.42.

Insider Transactions at Johnson & Johnson

In other news, EVP Ashley Mcevoy sold 73,323 shares of the stock in a transaction dated Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the sale, the executive vice president now owns 41,813 shares of the company’s stock, valued at $7,336,927.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Jennifer L. Taubert sold 76,923 shares of the firm’s stock in a transaction that occurred on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total value of $13,598,447.94. Following the sale, the executive vice president now owns 126,456 shares of the company’s stock, valued at $22,354,891.68. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Ashley Mcevoy sold 73,323 shares of the firm’s stock in a transaction that occurred on Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the completion of the sale, the executive vice president now directly owns 41,813 shares in the company, valued at approximately $7,336,927.11. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 300,750 shares of company stock valued at $52,311,677. 0.35% of the stock is currently owned by corporate insiders.

Johnson & Johnson Trading Down 0.3 %

NYSE JNJ opened at $173.43 on Tuesday. The firm’s 50-day moving average is $176.33 and its two-hundred day moving average is $171.44. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The stock has a market capitalization of $453.43 billion, a P/E ratio of 24.15, a PEG ratio of 3.28 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its earnings results on Tuesday, October 18th. The company reported $2.55 EPS for the quarter, beating analysts’ consensus estimates of $2.49 by $0.06. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company had revenue of $23.79 billion for the quarter, compared to analysts’ expectations of $23.44 billion. During the same quarter in the prior year, the company posted $2.60 earnings per share. Johnson & Johnson’s revenue for the quarter was up 1.9% compared to the same quarter last year. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be given a dividend of $1.13 per share. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 annualized dividend and a dividend yield of 2.61%. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.